Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma

Trevor W. Reichman, Phil Bahramipour, Alison Barone, Baburao Koneru, Adrian Fisher, Daniel Contractor, Dorian Wilson, Andrew Dela Torre, Kyunghee C. Cho, Arun Samanta, Lawrence Harrison

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) represents one of the most prevalent cancers worldwide. Most patients are not surgical candidates, and transarterial embolization (TAE) has been used to treat patients with unresectable HCC. The purpose of this study was to identify factors that predict survival in patients treated with TAE at a Western medical center. Review of a prospective database identified 345 patients treated for HCC at University Hospital (Newark, NJ) between July 1998 and July 2004. Of these patients, 109 patients underwent TAE. Eleven of these patients were subsequently treated surgically and excluded from this study. Of the remaining 98 patients, demographic data and laboratory values were analyzed to predict survival by univariate and multivariate analysis. Several factors, including hepatitis status, Child-Pugh classification, serum alpha fetoprotein levels <500 ng/ml, bilirubin <2.0 mg/dl, prothrombin time <16 seconds, platelet count <200 × 109/l, albumin >3.5 gm/dl, and multiple treatments, predicted survival by univariate analysis. Serum alpha fetoprotein levels, Child-Pugh classification, and hepatitis status were found by multivariate analysis to independently predict survival. These factors may help to select patients with unresectable HCC who might benefit from TAE.

Original languageEnglish (US)
Pages (from-to)638-645
Number of pages8
JournalJournal of Gastrointestinal Surgery
Volume9
Issue number5
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Hepatitis
Hepatocellular Carcinoma
Survival
Serum
alpha-Fetoproteins
Survival Analysis
Multivariate Analysis
Demography
Databases
Neoplasms

All Science Journal Classification (ASJC) codes

  • Surgery
  • Gastroenterology

Cite this

Reichman, Trevor W. ; Bahramipour, Phil ; Barone, Alison ; Koneru, Baburao ; Fisher, Adrian ; Contractor, Daniel ; Wilson, Dorian ; Dela Torre, Andrew ; Cho, Kyunghee C. ; Samanta, Arun ; Harrison, Lawrence. / Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. In: Journal of Gastrointestinal Surgery. 2005 ; Vol. 9, No. 5. pp. 638-645.
@article{42117bb82e194c0bb6ceb7336fca7266,
title = "Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma",
abstract = "Hepatocellular carcinoma (HCC) represents one of the most prevalent cancers worldwide. Most patients are not surgical candidates, and transarterial embolization (TAE) has been used to treat patients with unresectable HCC. The purpose of this study was to identify factors that predict survival in patients treated with TAE at a Western medical center. Review of a prospective database identified 345 patients treated for HCC at University Hospital (Newark, NJ) between July 1998 and July 2004. Of these patients, 109 patients underwent TAE. Eleven of these patients were subsequently treated surgically and excluded from this study. Of the remaining 98 patients, demographic data and laboratory values were analyzed to predict survival by univariate and multivariate analysis. Several factors, including hepatitis status, Child-Pugh classification, serum alpha fetoprotein levels <500 ng/ml, bilirubin <2.0 mg/dl, prothrombin time <16 seconds, platelet count <200 × 109/l, albumin >3.5 gm/dl, and multiple treatments, predicted survival by univariate analysis. Serum alpha fetoprotein levels, Child-Pugh classification, and hepatitis status were found by multivariate analysis to independently predict survival. These factors may help to select patients with unresectable HCC who might benefit from TAE.",
author = "Reichman, {Trevor W.} and Phil Bahramipour and Alison Barone and Baburao Koneru and Adrian Fisher and Daniel Contractor and Dorian Wilson and {Dela Torre}, Andrew and Cho, {Kyunghee C.} and Arun Samanta and Lawrence Harrison",
year = "2005",
month = "5",
day = "1",
doi = "10.1016/j.gassur.2004.11.002",
language = "English (US)",
volume = "9",
pages = "638--645",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "5",

}

Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma. / Reichman, Trevor W.; Bahramipour, Phil; Barone, Alison; Koneru, Baburao; Fisher, Adrian; Contractor, Daniel; Wilson, Dorian; Dela Torre, Andrew; Cho, Kyunghee C.; Samanta, Arun; Harrison, Lawrence.

In: Journal of Gastrointestinal Surgery, Vol. 9, No. 5, 01.05.2005, p. 638-645.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hepatitis status, child-pugh classification, and serum AFP levels predict survival in patients treated with transarterial embolization for unresectable hepatocellular carcinoma

AU - Reichman, Trevor W.

AU - Bahramipour, Phil

AU - Barone, Alison

AU - Koneru, Baburao

AU - Fisher, Adrian

AU - Contractor, Daniel

AU - Wilson, Dorian

AU - Dela Torre, Andrew

AU - Cho, Kyunghee C.

AU - Samanta, Arun

AU - Harrison, Lawrence

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Hepatocellular carcinoma (HCC) represents one of the most prevalent cancers worldwide. Most patients are not surgical candidates, and transarterial embolization (TAE) has been used to treat patients with unresectable HCC. The purpose of this study was to identify factors that predict survival in patients treated with TAE at a Western medical center. Review of a prospective database identified 345 patients treated for HCC at University Hospital (Newark, NJ) between July 1998 and July 2004. Of these patients, 109 patients underwent TAE. Eleven of these patients were subsequently treated surgically and excluded from this study. Of the remaining 98 patients, demographic data and laboratory values were analyzed to predict survival by univariate and multivariate analysis. Several factors, including hepatitis status, Child-Pugh classification, serum alpha fetoprotein levels <500 ng/ml, bilirubin <2.0 mg/dl, prothrombin time <16 seconds, platelet count <200 × 109/l, albumin >3.5 gm/dl, and multiple treatments, predicted survival by univariate analysis. Serum alpha fetoprotein levels, Child-Pugh classification, and hepatitis status were found by multivariate analysis to independently predict survival. These factors may help to select patients with unresectable HCC who might benefit from TAE.

AB - Hepatocellular carcinoma (HCC) represents one of the most prevalent cancers worldwide. Most patients are not surgical candidates, and transarterial embolization (TAE) has been used to treat patients with unresectable HCC. The purpose of this study was to identify factors that predict survival in patients treated with TAE at a Western medical center. Review of a prospective database identified 345 patients treated for HCC at University Hospital (Newark, NJ) between July 1998 and July 2004. Of these patients, 109 patients underwent TAE. Eleven of these patients were subsequently treated surgically and excluded from this study. Of the remaining 98 patients, demographic data and laboratory values were analyzed to predict survival by univariate and multivariate analysis. Several factors, including hepatitis status, Child-Pugh classification, serum alpha fetoprotein levels <500 ng/ml, bilirubin <2.0 mg/dl, prothrombin time <16 seconds, platelet count <200 × 109/l, albumin >3.5 gm/dl, and multiple treatments, predicted survival by univariate analysis. Serum alpha fetoprotein levels, Child-Pugh classification, and hepatitis status were found by multivariate analysis to independently predict survival. These factors may help to select patients with unresectable HCC who might benefit from TAE.

UR - http://www.scopus.com/inward/record.url?scp=20944432795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944432795&partnerID=8YFLogxK

U2 - 10.1016/j.gassur.2004.11.002

DO - 10.1016/j.gassur.2004.11.002

M3 - Article

VL - 9

SP - 638

EP - 645

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 5

ER -